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Because many ongoing clinical restenosis preven- 
tion trials are using quantitative angiography to 
assess whether a drug is capable of reducing the 
amount of intimal hyperplasia, quantitative angio- 
graphic risk factors for angiographic luminal nar- 
rowing after balloon angioplasty were determined, 
including stretch and elastic recoil at the dilatation 
site. Quantitative analysis was performed on 666 
lesions in 575 patients during angioplasty and at 
6-month follow-up. Stretch was defined as balloon 
diameter minus minimal luminal diameter (MLD) 
before angioplasty/reference diameter, and recoil 
as balloon diameter minus MLD after angioplas- 
ty/reference diameter. Multivariate analysis was 
used to yield independent risk factors for luminal 
narrowing at follow-up. Predictors of absolute 
change in MLD were (1) relative gain at angio- 
plasty (gain in millimeters normalized for refer- 
ence diameter) and (2) lesion length. To allow risk 
stratification, logistic regression analysis was ap- 
plied using the decrease in MLD as a binary out- 
come variable. A decrease in MLD at follow-up of 
20.72 mm was considered significant. Variables 
retained in the model were: relative gain >0.3 mm 
(rate ratio 2.9), relative gain 0.2 to 0.3 (rate ratio 
2.1), stenosis length 16.8 (rate ratio 1.7), and 
thrombus after angioplasty (rate ratio 2.6). Al- 
though stretch was significantly related to luminal 
narrowing at univariate analysis, it was not re- 
tained in the multivariate models. 
A large gain in lumen diameter at angioplasty, 
dilation of long lesions, and angiographically de- 
termined thrombus after angioplasty were found 
to be accompanied by more severe luminal nar- 
rowing at follow-up. 
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L uminal narrowing after coronary balloon angio- plasty still hampers the long-term vessel patency in a substantial percentage of patients. Several 
investigators have sought predictors of this untoward 
event.’ A multitude of patient-, procedural- and lesion- 
related variables have been found to predict long-term 
outcome of an angioplasty procedure, but because these 
findings are based on different restenosis criteria and 
varying angiographic follow-up rates accurate compari- 
son is difficult.2 
Conventionally, restenosis is determined by follow- 
up angiography. Computer-assisted automated edge de- 
tection techniques enhance objectivity and reproducibil- 
ity, and reduce the high inter- and intraobserver vari- 
ability inherent o visual interpretation of the coronary 
cineangiogram.3 Because many ongoing clinical resteno- 
sis prevention trials are using quantitative angiography 
to assess whether a pharmacologic agent is capable of 
reducing the amount of intimal hyperplasia (the under- 
lying cause of restenosis), it is important o determine 
quantitative angiographic risk factors for angiographic 
luminal narrowing after balloon angioplasty. At the mo- 
ment it is unknown which angiographic parameters are 
associated with an increased risk for luminal narrowing. 
Both over- and underdilating are reported to be associ- 
ated with an increased risk for restenosis. Overdilation 
may trigger an excessive hyperplastic response, because 
of its relation with dissection and deep arterial injury 
with increased platelet activation.4J Stretching of the 
vessel itself may also be an important stimulus for the 
Iibroproliferative vessel reaction by being a determinant 
of medial smooth muscle injury6 and by changing the 
phenotype of the medial smooth muscle cells from con- 
tractile to synthetic.’ Elastic recoil after balloon defla- 
tion has (at least theoretically)8,9 been linked to luminal 
narrowing at follow-up. Underdilation may leave a sig- 
nificant residual stenosis with a possible increased tur- 
bulence, platelet activation and restenosis.‘O 
In this study, quantitative lesion measurements be- 
fore and after angioplasty, and at follow up were ob- 
tained and correlated with loss in minimal luminal di- 
ameter (MLD) at follow-up. To examine the effect of 
degree of arterial stretching and elastic recoil on lumi- 
nal narrowing at follow-up, balloon diameters were 
measured. Stretch was defined as the difference in 
mean balloon diameter and MLD before angioplasty,6 
and elastic recoil as the difference between mean 
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balloon diameter and MLD after angioplasty.9 Both 
stretch and recoil were normalized for reference diame- 
ter to correct for the influence of vessel size and are 
therefore dimensionless. 
METHODS 
The study population consisted of 697 patients who 
were originally enrolled in 6 European centers for the 
CARPORT trial” (see Appendix). In this randomized, 
double-blind, placebo-controlled trial, a novel throm- 
boxane AZ receptor antagonist (GR32191) was inves- 
tigated for its ability to prevent restenosis after primary 
coronary angioplasty. Follow-up of these patients was 
performed on a prospective basis, and all patients 
agreed to undergo repeat angiography at 6 months. 
Neither angiographic nor clinical benefit of the com- 
pound could be demonstrated,” so the placebo and ac- 
tive treatment groups could be pooled for the present 
study. All patients with both stable and unstable angina, 
and angiographically proven native coronary artery dis- 
ease who were scheduled for primary angioplasty were 
considered for participation in the trial. Specific exclu- 
sion criteria are listed in Table I. A screening log was 
maintained at 2 centers to assess the relative frequencies 
of these exclusion criteria. 
Unsuccessful angioplasty procedures occurred in 48 
patients (6.9%). Successful angioplasty was defined as 
<50% residual stenosis by visual inspection of the an- 
giogram after angioplasty, and no occurrence of in-hos- 
pital complications (death, acute myocardial infarction, 
repeat angioplasty, aortocoronary bypass grafting or re- 
currence of symptoms). 
Five hundred seventy-five (88.6%) of the 649 pa- 
tients with a successful angioplasty had a follow-up an- 
giogram suitable for quantitative angiography. Reasons 
for not completing the study were late death (n = 2), 
contraindication for repeat catheterization (n = 18), 
and refusal (n = 46). Eight follow-up angiograms were 
unsuitable for quantitative analysis. 
Angioplasty procedure and fotlow-up angiography: 
Coronary angioplasty was performed with a steerable, 
movable guidewire system by the femoral route. Stan- 
dard available balloon catheters were used. Choice of 
balloon type and brand, as well as inflation duration 
and pressure, were left to the discretion of the angio- 
plasty operator. At the beginning of the angioplasty pro- 
cedure, all patients received 10,000 IU of intravenous 
heparin for the first 2 hours; afterward, they received 
5,000 III/hour for as long as the procedure continued. 
All patients received 10 mg of nifedipine every 2 hours 
for the first 12 hours after angioplasty. Thereafter they 
received 20 mg of slow-release nifedipine tablets 3 times 
during the second day after angioplasty. 
Four coronary angiograms were obtained in each pa- 
tient, 1 just before angioplasty, 1 during maximal infla- 
tion of the largest balloon used, 1 immediately after the 
procedure, and 1 at follow-up. Angiograms were record- 
ed in such a way that they were suited for quantitative 
analysis by the Cardiovascular Angiography Analysis 
System (CAAS). All necessary details of the procedure 
were recorded, and drawings of the segments to be ana- 
lyzed were made. For calibration purposes, catheter tips 
TABLE I Reasons for Exclusion of 1,318 of 1,614 Screened 
Patients in Two of Six Participating Centers 
Reason No. (%I 
Insufficient lead-in time* 235 (18) 
Use of platelet inhibiting drugs or nonsteroid antiinflam- 352 (27) 
matory drugs in 7 days preceding study 
Refusal to participate or undergo 6-month 
recatheterization 
364 (28) 
Currently receiving oral anticoagulant drugs 
Angioplasty for restenosis 
Acute myocardial infarction in 2 weeks preceding angio- 
Nasty 
119 (9) 
105 (8) 
52 (4) 
Bypass graft dilatation 
History of obstructive airway disease 
History of peptic disease or upper GI bleeding 
Previous participation in the trial 
Other severe disease 
Participation in other trial 
History of intolerance to aspirin 
Aged < 2 1 years 
Pregnant or likely to become pregnant during study 
Total 
39 (3) 
26 (2) 
10 (1) 
2 (0.2) 
6 (0.5) 
6 (0.4) 
l(O.1) 
l(O.1) 
0 (0) 
1,318 (100) 
*Urgent referrals outside working hours. 
GI = gastrointestinal. 
were cut off for later measurement with a microcaliper. 
To standardize the method of data acquisition and to 
ensure exact reproducibility of the angiographic studies, 
measures were obtained as described previously.*J* All 
angiograms were processed and analyzed at a central 
core laboratory (see Appendix). 
The follow-up coronary angiogram was performed 
after 6 months. If symptoms recurred within 6 months, 
coronary angiography was performed earlier. If no deli- 
nite restenosis was present and follow-up time was <4 
months, the patient was asked to undergo another coro- 
nary arteriogram at 6 months. 
Quantitative angiography (Figure 1): All cineangio- 
grams were analyzed using the CAAS that has been 
described and validated previously.13J4 A computer-de- 
rived reconstruction of the original arterial dimension at 
the site of obstruction (assuming there is no disease 
present) is used to define the interpolated reference di- 
ameter. The length of the obstruction is determined 
from the diameter function on the basis of curvature 
analysis and is expressed in millimeters. In addition, this 
technique allows for the calculation of an eccentricity 
index9 of the lesion. The index ranges from 0 (severely 
eccentric) to 1 (perfectly symmetric). Because the algo- 
rithm can not measure total occlusions, avalue of 0 mm 
was substituted for the MLD. In these cases, the refer- 
ence diameter after angioplasty was substituted for that 
before. The mean change in MLD from angiography 
after angioplasty to follow-up and from before to after 
angioplasty was derived from matched angiographic 
projections. Balloon artery ratio was defined as the ratio 
of the mean balloon diameter measured in a nonfore- 
shortened projection and the reference diameter of the 
dilated segment. Three parameters were calculated that 
reflect the changes occurring during angioplasty (Fig- 
ure 2). These were (1) stretch (mean balloon diameter 
minus MLD before angioplasty/reference diameter), 
(2) elastic recoil (mean balloon diameter minus MLD 
after angioplasty/reference diameter) and (3) relative 
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TABLE II Baseline Characteristics 
Number of patients 
Age (years) 
Men/women 
Time to follow-up angiography (days) 
Number of narrowings dilated 
Left anterior descending artery 
Left circumflex artery 
Right coronary artery 
Prior myocardial infarction 
Prior coronary bypass surgery 
Prior angioplasty at other site 
56 zk 9 
464/111 (81%)/(19%) 
172 241 
666 
321 (48%) 
154 (23%) 
191(29%) 
221 (38%) 
15 (3%) 
10 (2%) 
gain achieved by angioplasty (MLD after minus MLD 
before angioplasty/reference diameter). All 3 parame- 
ters were normalized for interpolated reference diame- 
ter to correct for vessel size and are therefore dimen- 
sionless. Intracoronary thrombus was defined as an 
intraluminal filling defect visible in all projections or 
dye staining at the site of a total occlusion (interob- 
server concordance rate for the assessment of intracoro- 
nary thrombus in the core laboratory 89%). 
Significant luminal narrowing: To predict significant 
luminal narrowing after angioplasty, we chose a cutoff 
point above which significant deterioration in MLD is 
likely. We have found a change in MLD of 10.72 mm 
to be a reliable indicator of angiographic progression of 
vessel narrowing.*J4 This value takes into account the 
limitations of coronary angiographic measurements and 
represents twice the long-term variability for repeat 
measurements of a coronary obstruction using CAAS.14 
This variability reflects the long-term random variation 
in lesion measurements from coronary angiograms ob- 
tained at different catheterization sessions using CAAS. 
The use of 1 standard deviation would include 68.3% of 
the measurement variability, whereas the use of 2 stan- 
/ 
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I 
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I 
FIGURE 1. Graphic representation of quantitative angiograph- 
ic measurements. Upper pane/ represents stenosed arterial 
segments. Lower pane/ is diameter function curve. Length of 
analyzed segment is depicted on x axis, and vessel diameter 
on y axis. Extent of obstruction = tesion length. Lesion length 
is determined with curvature analysis of descending and as- 
cending limb of diameter function curve at site of minimal lu- 
minal diameter (MLD). Eccentricity is determined at site of 
MLD and calculated as a/b. 
TABLE Ill Quantitative Angiographic Data of 666 Lesions 
Mean 5 SD (range) 
Minimal luminal diameter (mm) 
Before angioplasty 1.04 + 0.37 (0.00-2.83) 
After angioplasty 1.76 k 0.38 (0.85-3.04) 
Follow-up 1.48 k 0.59 (O-3.15) 
Diameter stenosis (%) 
Before angioplasty 60 f 13 (33-100) 
After angioplasty 34 k 9 (6-65) 
Follow-up 45 2 19 (4-100) 
Difference in minimal luminal diameter 
Before and after angioplasty (mm) 0.75 2 0.40 
After angioplasty-follow-up (mm) 0.28 rk 0.52 
Relative gain at angioplasty* 0.28 2 0.16 
Difference in % diameter stenosis 
Before and after angioplasty (%I 26 zk 14 
After angioplasty-follow-up (%) 11% 19 
*See Figure 2. 
dard deviations (2 X 0.36 = 0.72 mm) includes 95.5%. 
Therefore, a difference in MLD of more than twice the 
long-term measurement variability can be considered 
indicative of significant luminal narrowing. To compare 
the criterion of change in MLD with a more conven- 
tional criterion of restenosis, analyses were also per- 
formed with the 150% diameter stenosis criterion. 
Data analysis: Data were analyzed using the BMDP 
statistical software package (University of California, 
Berkeley, California). In a univariate analysis (unpaired 
Student’s t test), those continuous quantitative angio- 
graphic variables that were related to a significant loss 
in MLD were selected. These variables together with 
elastic recoil and balloon artery ratio (known from the 
literature to be related to restenosis) were entered in a 
stepwise multiple linear regression analysis to identify 
variables, with an independent contribution to the pre- 
diction of absolute decrease in MLD as a continuous 
variable (see Appendix). 
To allow risk stratification, logistic regression analy- 
sis using indicator variables was subsequently applied, 
with the decrease in MLD (using a decrease of 10.72 
mm as the cutoff value), and the 50% diameter stenosis 
MLD (mm1 
3 
BALLOON STRETCH RECOIL 
2.5 
2 
1.5 
1 
0.5 
0 
I 
FIGURE 2. Graphic representation of terms used. Mean abso- 
lute values of variables are shown. Stretch, recoil and gain 
were normalized for vessel size (reference diameter) to correct 
for vessel size. BALLOON = balloon mean diameter; F-UP = 
follow-up MLD; MLD = minimal luminal diameter; POST = 
MLD after angioplasty; PRE = MLD before angtoplasty. 
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criterion as binary outcome variables, because the logis- 
tic regression coefficients are easily related to adjusted- 
rate ratios for the different variables. Continuous 
variables were therefore grouped into 3 equally sized 
subgroups (tertiles). Three subgroups were selected to 
enable assessment of trends in the incidence of a 10.72 
mm decrease and because more subgroups would weak- 
en the strength of associations. The incidence of a 
10.72 mm decrease was determined in each subgroup. 
If a trend for a higher incidence was present in each 
consecutive subgroup, then the one with the lowest inci- 
dence was chosen as the reference group. If no trend for 
an increasing incidence of a 10.72 mm decrease was 
present in each consecutive subgroup, the one with the 
highest incidence was compared with the 2 others com- 
bined (reference group). 
Distortion of the relation between different determi- 
nants of a 10.72 mm decrease in MLD and the inci- 
dence of a decrease 10.72 mm (confounding) caused by 
unequal distributions of these determinants among the 
tertiles was eliminated by multivariate logistic regres- 
sion analysis. Description of the multivariate logistic re- 
gression model and of the methodology to obtain adjust- 
ed-rate ratios and 95% confidence intervals (CIs) is giv- 
en in the Appendix. 
RESULTS 
Baseline characteristics of the 575 patients with 
quantitative angiographic follow-up are summarized in 
Table II. 
Overall quantitative angiographic findings before 
and after angioplasty, and at follow up are presented in 
Table III. Reference diameter was not different before 
and after angioplasty, and at follow up (2.64 f 0.56, 
2.71 f 0.54 and 2.71 f 0.56 mm, respectively), suggest- 
ing an accurate control of vasomotion during the 3 angi- 
ographic studies. 
The incidence of significant luminal narrowing (2 
0.72 mm) was 17.7% (117 of 666 lesions). The inci- 
dence of restenosis according to the 50% diameter ste- 
nosis criterion was 33% (220 of 666 lesions). 
Univariate analysis: With univariate analysis (Table 
IV), the following quantitative angiographic variables 
were associated with a 20.72 decrease in MLD: MLD 
before and after angioplasty, increase in MLD obtained 
by angioplasty, length of obstruction, and stretch. Thir- 
ty-six lesions were totally occluded before angioplasty, 
and therefore, stenosis length and eccentricity coefti- 
cient could not be measured. For comparison with the 
traditional restenosis criterion of >50% diameter steno- 
sis at follow-up, values were also broken down accord- 
ing to this criterion. The apparent difference in MLD 
after angioplasty for the 2 criteria, and the absence of a 
difference in relative gain in the I and >50% diameter 
stenosis at follow-up groups are explained later. 
More stretching was accompanied by more recoil. 
The amount of recoil in the tertile with the highest 
amount of stretch (20.65) was 0.42 compared with 
0.25 in the other 2 tertiles combined (stretch <0.65) (p 
<O.OOOl; unpaired t test). 
Multiple linear regression analysis: The variables 
significantly related to a LO.72 mm decrease in MLD 
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in the univariate analysis, as well as elastic recoil and 
balloon artery ratio, were entered in the multiple linear 
regression analysis. Only relative gain in MLD at angio- 
plasty, and the length of the stenosis were retained in 
the final model. The amount of stretch induced on the 
vessel wall, although significantly higher in the group of 
lesions with a 10.72 mm decrease in MLD with uni- 
variate analysis, was not retained in the stepwise multi- 
ple linear regression model. 
Logistic regression analysis: The variables retained 
in the multiple linear regression analysis, and 6 vari- 
ables known from the literature to be related to resteno- 
sis were entered in the logistic regression model. The 
latter variables were vessel dilated,15 total occlusion be- 
fore angioplasty, * 6angiographically determined throm- 
bus before and after angioplasty, elastic recoil and bal- 
loon artery ratio. Thrombi before and after angioplasty 
were included, because it has been reported that throm- 
botic lesions are longer in length and that total occlu- 
sions frequently have a thrombotic omponent. Further- 
more it is conceivable that thrombotic lesions have a 
larger relative gain and low elastic recoil. Angiographi- 
tally, a thrombus was observed in 32 of 666 lesions 
before angioplasty (5%) and in 16 (1.6%) after. Type 
of trial medication (placebo or active treatment) was 
forced into the model to rule out any effect on the anal- 
ysis results. Because dilation of totally occluded coro- 
nary arteries is associated with a higher restenosis 
rate,16 and it could be argued that in these lesions in 
general a higher gain at angioplasty will be achieved, 
this determinant was also forced into the model to ac- 
count for any confounding effect. Totally occluded le 
sions did not have length measurements; herefore, the 
indicator variable for lesion length was set to 0 in these 
cases. 
A relative gain at angioplasty of 10.3 had an adjust- 
ed-rate ratio (RR) for developing a decrease in MLD 
20.72 mm of 2.9. This means that the risk for develop- 
ing a decrease of LO.72 mm with at least this relative 
gain is 2.9 times as high as it is for lesions with a rela- 
tive gain <0.2. The 95% CIs were 1.9 to 4.5. Other 
variates retained were relative gain between 0.2 and 0.3 
(RR 2.1, 95% CI 1.3 to 3.3), lesion length 16.8 mm 
(RR 1.7, 95% CI 1.2 to 2.3) and thrombus after angio- 
plasty (RR 2.6, 95% CI 1.1 to 6.2). Total occlusion be 
fore angioplasty and use of active trial medication had 
no significant independent predictive contribution to a 
significant decrease in MLD (RR 1.5, 95% CI 0.8 to 
3.0, and RR 1.1, 95% CI 0.7 to 1.5, respectively). 
Stretch, balloon artery ratio, elastic recoil, type of ves- 
sel, and thrombus before angioplasty were not retained 
in the final logistic regression model. 
To assure that total occlusions did not unduly influ- 
ence the results, analysis was repeated excluding these 
lesions. Adjusted-rate ratios were similar to those in the 
original analysis (relative gain 0.2 to 0.3: RR 2.2, 95% 
CI 1.4 to 3.4; relative gain >0.3: RR 3.2, 95% CI 2.0 to 
5.1; lesion length 26.8 mm: RR 1.8,95% CI 1.2 to 2.6). 
The logistic regression analysis was also performed 
with the >50% diameter stenosis criterion as dependent 
variable. Type of trial medication was again forced into 
the model. A lesion length of 26.8 mm (RR 1.3, 95% 
CI 1.1 to 1.4) and thrombus after angioplasty (RR 1.8, 
95% CI 1.0 to 3.1) were retained in the final model. The 
use of GR32191 as trial medication had an adjusted- 
rate ratio of 0.98 (95% CI 0.9 to 1.1). 
DISCUSSION 
Luminal narrowing after coronary angioplasty is a 
complex process that is only partially understood. Histo- 
logic studies of coronary arteries after dilation obtained 
by either autopsy or atherectomy have provided direct 
and indirect evidence that strongly supports the concept 
of intimal hyperplasia or proliferation of smooth muscle 
cells of medial or intimal origin as the underlying cause 
of luminal narrowing after angioplasty.5J7 
The 1 factor most strongly associated with luminal 
narrowing in this study was the relative gain in MLD 
achieved by angioplasty. This probably best reflects 
the combination of deep arterial injury and reversible 
stretch imposed on the diseased vessel wall. Deep arteri- 
al injury and smooth muscle cell stretch are known 
stimuli for smooth muscle cell proliferation. It is now 
believed that after balloon injury, denudation of endo- 
thelial cells is followed by platelet adhesion and aggre- 
gation with the release of growth factors (notably plate- 
let-derived growth factor), and vaso- and platelet-active 
substances. Extensive damage to the endothelial lining 
of the vessel, which is always present after balloon dila- 
tation, may upset he balance between the inhibiting ef- 
fect of endothelial-derived heparin sulphates on medial 
smooth muscle cell growth, and the mitogenic and che- 
motactic effect of platelet-derived growth factor and of 
other growth factors on these cells.‘* Not only platelet 
exposure to the vascular layers, but also direct injury to 
the smooth muscle cells is reported to begin the prolifer- 
ative response.19 So, as suggested by Liu et ak20 a major 
factor that determines the amount of intimal hyperpla- 
sia after balloon angioplasty seems to be the extent of 
permanent mechanical injury inflicted upon the vessel 
wall. Animal experiments with an atherosclerotic rab- 
bit model have shown that the combination of balloon 
oversizing and long inflations caused most damage to 
the vessel wall and was associated with the greatest de- 
gree of intimal hyperplasia at follow-up.21 Similarly 
Schwartz et a122 described an aggressive proliferative re- 
sponse in a porcine model as a result of severe stent 
oversizing. This effect, which they attributed to penetra- 
tion of the internal elastic membrane by the stent wires 
and subsequent deep arterial injury, was much less pro- 
nounced when the stent was matched more closely to 
the vessel diameter. This was recently also demon- 
strated in a clinical stent study.23 Implantation of an 
oversized stent was combined with a more aggressive 
hyperplastic reaction than when the. stent was more 
closely matched to the receiving artery. 
Dilation of totally occluded coronary arteries is 
known to be associated with a higher restenosis rate.16 
However, total occlusions forced in the logistic regres- 
sion model did not have a significant independent con- 
tribution to the prediction of a decrease in MLD of 
10.72 mm, probably due to an unequal distribution of 
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thrombus after angioplasty over totally occluded and 
patent arteries; 6 of 36 (16.7%) total occlusions before 
angioplasty had a thrombus after versus 10 of 630 
(1.5%) patent arteries. It could be argued that in total 
occlusions in general, a higher gain at angioplasty will 
be achieved, and that this may be the explanation for 
the relation found between gain and restenosis. In our 
population, 36 total occlusions were successfully dilated 
with a restenosis rate at follow-up of 33.3% (12 of 36; 
10.72 mm criterion). However, if total occlusions be- 
fore angioplasty are left out of the analysis, a high rela- 
tive gain and lesion length were still associated with a 
significant adjusted risk for a decrease of 10.72 mm. 
The fact that angiographically determined thrombus 
at the dilation site before angioplasty was not found to 
be a risk factor for a significant decrease in MLD tends 
to confirm our earlier report that showed no difference 
in significant luminal narrowing for patients with unsta- 
ble angina. 24 Angiographically demonstrable intracoro- 
nary thrombus after angioplasty is the angiographic 
proof that massive platelet aggregation, thrombin acti- 
vation and fibrin formation have occurred with the sub- 
sequent release of vasoactive substances25 and growth 
factors involved in the fibroproliferative restenosis pro- 
cess. Furthermore, a recent postmortem study showed 
that part of early (<l month) restenosis lesions consist- 
ed of mural thrombus.5 
Longer lesions were found to be associated with a 
higher relative risk for restenosis at follow-up. In these 
lesions, more smooth muscle is possibly exposed to inju- 
ry and platelet adhesion, which enhances the risk of re- 
stenosis. Several studies have indeed shown that long 
lesions and vessel areas containing thick atherosclerotic 
plaques are related to an increased incidence of dissec- 
tions, and thus more extensive vessel wall injury.26,27 
Several experimental studies have suggested that di- 
lation of the vessel wall is a stimulus for smooth muscle 
cell proliferation and later intimal hyperplasia,ls,21 ei-
ther by stretch or direct injury to smooth muscle cells. 
In the present study, univariate analysis (Table IV) 
showed that a significantly higher amount of stretch 
was induced on the vessel wall in the group with a 
10.72 mm decrease in MLD. These findings correlate 
with the observations by Fischell et al6 that showed a 
relation between the degree of arterial stretching and 
the severity of smooth muscle injury as determined by 
reduction of vasoconstrictor responsiveness and by histo- 
pathological examination, and, as emphasized previous- 
ly, more smooth muscle injury has been shown to en- 
hance intimal hyperplasia in a more controlled animal 
model.21 However, after elimination of the unequal dis- 
tribution of stretch over the various determinants of a 
significant decrease in MLD by multivariate analysis, 
stretch was not found to be an independent predictor of 
luminal narrowing. 
Elastic recoil, as measured within minutes after the 
last dilatation9 was not found to be a determinant of 
restenosis. This finding is at variance with another re- 
port8 that suggests that recoil may be a factor in lumi- 
nal narrowing observed at follow-up. It may be that re- 
coil is not an instantaneous phenomenon, but rather ex- 
erts its effect over a longer period of time, and thus 
could not be picked up by the angiogram after angio- 
plasty that was obtained within minutes after the final 
balloon deflation. 
Study limitations: To allow risk stratification for de- 
crease in MLD with the use of multivariate analysis 
techniques, a cutoff point had to be chosen that accu- 
rately describes those lesions that underwent a signifi- 
cant deterioration at follow-up. The rationale for the 
0.72 mm criterion as a marker for significant luminal 
narrowing is outlined previously. This criterion is not 
meant to be a restenosis criterion in this study, because 
that also implies some sort of functional measure of le- 
sion severity at follow-up. The frequently used delini- 
tion of 50% diameter stenosis at follow-up is historically 
based on the physiologic oncept of coronary flow re- 
serve introduced by Gould et a12* in 1974 and is used 
because it represents the approximate value in animals 
with normal coronary arteries at which blunting of the 
hyperemic response occurs. Although this value may be 
of some relevance in determining a significant stenosis 
in human atherosclerotic vessels, it tells us nothing 
about the dynamic behavior of the restenosis process. If 
the 50% diameter stenosis at follow-up criterion is used, 
lesions with a suboptimal angioplasty result will prefer- 
entially be selected (i.e., have to undergo a small de- 
crease in MLD to be termed restenosed). This is reflect- 
ed by the lower MLD after angioplasty in the >50% 
diameter stenosis group (Table IV) compared with that 
of the >50% group. The mean percent diameter stenosis 
after angioplasty in the group with a relative gain <0.2 
was 40%; in the group with a relative gain between 0.2 
and 0.3 this was 34%, and in that with a gain 20.3 this 
was 28%. This means that lesions with a small relative 
gain generally tend to have a poorer result after angio- 
plasty and are close to the 50% diameter stenosis cutoff 
point. Furthermore, because the long-term variability of 
diameter stenosis measurements u ing CAAS is 6.5%,14 
a significant number of lesions will be defined as reste- 
nosed, while in fact no change has occurred. The mean 
percent diameter stenosis after angioplasty was 31% for 
those lesions fulfilling the 20.72 mm criterion, and 37% 
for the >50% diameter stenosis criterion. Therefore, 
both criteria describe different populations at follow-up, 
and if one wants to examine risk factors for change in 
luminal diameter, the 50% diameter stenosis criterion is 
inappropriate. 
The definition of stretch was essentially the same as 
that used by Fischell et al6 in a series of in vitro experi- 
ments with isolated, perfused, nondiseased, whole vessel 
segments of rabbit aortas and dog carotid arteries. In 
our population of diseased arterial segments, stretch 
was calculated as the difference between mean balloon 
diameter and MLD before angioplasty divided by the 
relaxed reference diameter, because this reflects the 
maximal focal stretch induced on the vessel wall. This 
presumes that no compression or extrusion of the ath- 
erosclerotic plaque occurred during angioplasty. 
The immediate luminal narrowing after balloon de- 
flation that we attributed to elastic recoil could also be 
caused by spasm or nonocclusive mural thrombus for- 
CHANGES AT ANGIOPLASTY AND RESTENOSIS 589 
mation. It has been shown that the administration of 
intracoronary nitrates after angioplasty abolishes possi- 
ble spasm. 19,29 Furthermore, the mean reference diame- 
ter after angioplasty was not different from that before. 
Our angiogram after angioplasty was obtained within 
minutes after the final balloon deflation, and although 
we cannot rule out the possibility of mural thrombus to 
occur in this short time period, we believe that it cannot 
explain the observed immediate 30% reduction in MLD. 
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APPENDIX 
Linear regression analysis: Stepwise multiple linear 
regression analysis was performed (BMDP statistical 
package, program 2R) to assess the relation between 
the variables mentioned in Methods (independent vari- 
ables = Xi) and the decrease in MLD from the angio- 
gram before angioplasty to that at follow-up (dependent 
variable = Y): Y = A + Zi BiXi, where A is the inter- 
cept and Bi is the ith regression coefficient. The stan- 
dard 2R criteria of F >4 for inclusion, and F <3.9 for 
elimination were used. 
Multivariate logistic regression analysis: Multiple 
logistic regression analysis was performed with the 
BMDP statistical package (program LR). The linear lo- 
gistic model relates a probability (P) for the outcome 
event to the value of a baseline characteristic (X) using 
the linear logistic function: P = l/l + e-(a+bX). The re- 
lation between variables retained in the multiple linear 
regression model and restenosis according to the 0.72 
mm criterion was expressed in a multivariate logistic 
regression model. Also, a set of variables reported to be 
predictors of restenosis was selected. All these variables 
were entered in a model, 1 at a time. The model to 
describe the risk for developing restenosis was fitted to 
the data of 595 lesion dilatations with balloon measure- 
ments. The standard LR criteria of p <O. 1 for inclusion, 
and p >0.15 for elimination were used. Adjusted-rate 
ratios and 95% confidence intervals were obtained ac- 
cording to the method of Miettinen30 by the following 
formulas, in which the incidence of restenosis was en- 
tered for all variates (Xi) other than the variates for 
which the adjusted-rate ratio was determined; 1was en- 
tered for the variate under study (Xj) in the numerator 
and 0 in the denominator: 
Rate ratio = [l + exp(-(intercept + CibiXi + bjl))]-’ 
[l + exp(-(intercept + ZibiXi + b,O))]-’ 
95% confidence interval: rate ratio(1*1.96/(bj/SE)). 
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de Brabois (Nancy, France): Nicolas Danchin, MD,* 
Yves Juilliere, MD, A. Hueber, MD, Francois Cherrier, 
MD; Onze Lieve Vrouw Ziekenhuis (Aalst, Belgium): 
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